Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 46,600 shares granted to two non-executive employees under the 2018 Plan. The grants were approved March 2, 2026 and comply with Nasdaq Listing Rule 5635(c)(4).
The options carry a 10-year term, an exercise price of $42.49 per share (closing price on March 2, 2026), and vest 25% after one year then monthly at 1/48th thereafter, subject to continuous service and plan terms.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SYRE
+2.29%
+2.29%Session close to close
In the Mar 9 session, SYRE gained 2.29%, reflecting a moderate positive market reaction.
This announcement details routine equity inducement grants of 46,600 stock options at an exercise pr...
Analysis
This announcement details routine equity inducement grants of 46,600 stock options at an exercise price of $42.49 with standard four-year vesting under the 2018 Plan. It follows prior inducement awards tied to new hires and complements recent financial strength, including $756.5 million in cash and securities as of year-end 2025. With an effective $500,000,000 shelf and a defined ATM capacity, investors may track how ongoing hiring, clinical milestones, and any future offerings interact over time.
Key Figures
Inducement options:46,600 sharesOption exercise price:$42.49Option term:10 years+5 more
8 metrics
Inducement options46,600 sharesAggregate stock options granted to two non-executive employees under 2018 Plan
Option exercise price$42.49Exercise price equal to SYRE Nasdaq closing price on March 2, 2026
Option term10 yearsTerm of inducement stock options granted on March 2, 2026
Shelf capacity$500,000,000Maximum aggregate offering under Form S-3 base prospectus dated Feb 19, 2026
ATM program size$154,059,875Common stock under TD Cowen at-the-market sales agreement in S-3 prospectus
Cash & securities$756.5 millionCash, cash equivalents and marketable securities as of Dec 31, 2025
Q4 2025 net loss$62.5 millionQuarterly net loss for Q4 2025 vs $56.3 million in 2024
Shares outstanding78,540,164Common shares outstanding as of Feb 12, 2026 (Form 10-K)
Inducement option grant of 108,155 shares for new Chief Commercial Officer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, especially clinical and financial updates, has generally coincided with positive price reactions, while routine inducement grants have produced smaller, mixed moves.
Recent Company History
Over the past few months, Spyre has released a series of catalysts, including fourth quarter and full-year 2025 results on Feb 19, 2026 with strong cash of $756.5 million and multiple Phase 2 programs advancing, which saw a 14.28% gain. Scientific data at the 21st ECCO Congress and upcoming conference participation also drew modestly positive reactions. By contrast, prior inducement award grants in Jan–Feb 2026 led to relatively small price moves, framing today’s awards as part of an ongoing hiring and incentive pattern.
"antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases"
Inflammatory bowel disease is a group of long‑lasting conditions that cause repeated inflammation of the digestive tract, leading to symptoms like belly pain, diarrhea, bleeding and weight loss. For investors it matters because IBD drives steady demand for medications, ongoing clinical trials, medical devices and diagnostics; think of it as a chronic maintenance market where successful treatments can create predictable, long‑term revenue streams and regulatory milestones can move stock prices.
rheumatic diseasesmedical
"standard of care for inflammatory bowel disease and rheumatic diseases"
Rheumatic diseases are a group of conditions that cause chronic inflammation, pain, stiffness, or damage in joints, muscles, and connective tissues—think of the body’s hinges and supporting ropes becoming swollen or worn. For investors, they matter because treatments, long-term care needs, and prevalence influence demand for drugs, medical devices, and services; successful therapies can change a company’s sales outlook much like a new engine changing a car’s performance.
equity inducement awardsfinancial
"shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
Nasdaq Listing Rule 5635(c)(4)regulatory
"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 46,600 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on March 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $42.49, the closing price per share of Spyre's common stock as reported by Nasdaq on March 2, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com
FAQ
What did Spyre Therapeutics (SYRE) grant in the March 6, 2026 announcement?
Spyre granted stock options to purchase an aggregate of 46,600 shares to two non-executive employees. According to the company, the grants were approved March 2, 2026 and structured as inducement awards under the 2018 Plan.
What are the exercise price and term for the SYRE inducement stock options?
The options carry a $42.49 exercise price and a 10-year term. According to the company, $42.49 equals Spyre's Nasdaq closing price on March 2, 2026, the approval date of the grants.
How do the SYRE options vest for the newly hired employees?
Options vest 25% after the first anniversary, then 1/48th monthly thereafter. According to the company, vesting is subject to continuous service with Spyre through each applicable vesting date.
Why did Spyre issue these inducement awards under Nasdaq rules for SYRE?
The awards were approved as inducement grants that were material to each employee’s acceptance of employment. According to the company, the grants comply with Nasdaq Listing Rule 5635(c)(4) for new-hire inducement awards.
Are the SYRE stock options subject to any plan terms or conditions?
Yes, the options are subject to the terms of the Spyre Therapeutics 2018 Equity Inducement Plan, as amended. According to the company, exercise, vesting and other conditions follow the 2018 Plan provisions.
